# HANDOVER — TrueGround OCD / LOT 02

Status: READY FOR REVIEW
Date: 2026-09-16

## 1. Identity

- Project: TrueGround OCD
- Repository: `hraaaaf/trueground`
- Lot: `LOT 02 — TrueGround client isolation + OCD capsule contract`
- Working branch: `lot/02-client-isolation-capsule-contract`
- Parent/base branch for this lot: `lot/01-iamina-core-inspection`
- Parent/base SHA at LOT 02 start and handover preparation: `c5380cae770c11b958cb4a0a54152da40030df71`
- Repository HEAD immediately before this handover commit: `47c40b7e23d3d4aca4219a83610c47bc23b7a66f`
- Draft PR: `#3 — docs: LOT 02 define TrueGround client isolation and OCD capsule contract`
- PR base: `lot/01-iamina-core-inspection`
- PR state before handover commit: OPEN / DRAFT / NOT MERGED
- Merge authorization: **NOT GRANTED**
- Deployment authorization: **NOT GRANTED**
- IAmina Core modification authorization: **NOT GRANTED**

Important: committing this handover advances the LOT 02 branch HEAD beyond the pre-handover SHA above. Any future window must re-check the live branch, PR, divergence, review state, CI/checks and current IAmina source before acting.

## 2. GOAL / SUCCESS / PROOF

### GOAL

Define the smallest auditable architecture contract that allows TrueGround/OCD to reuse proven IAmina Core primitives while remaining a separate client/product from the Diabetes client under the product-owner-approved Option A boundary.

### SUCCESS

- Current TrueGround repository/branches/PR state verified before modification: **met**.
- Current `hraaaaf/IAMINA-MVP main` re-inspected rather than trusting LOT 01 SHA: **met**.
- Reusable IAmina primitives identified from live source: **met**.
- Generic IAmina Core vs TrueGround/OCD ownership documented: **met**.
- Separate deployment/auth/data/memory/secrets/provider/frontend boundaries documented: **met**.
- Prompt/policy/eval ownership documented: **met**.
- Routing/module-registration and current Diabetes-coupled composition constraints documented: **met**.
- Account deletion/export/retention responsibility documented: **met**.
- Forbidden dependency directions documented: **met**.
- Immutable shared-Core version/update strategy documented without inventing an existing package: **met**.
- Future static/integration checks against OCD→Core leakage, Diabetes coupling and cross-client data/config coupling documented: **met**.
- Mandatory adversarial specialist passes recorded: **met with documented independence limitation**.
- No Loop UI, Compulsion Firewall algorithm, ERP behavior or detailed DB schema introduced: **met**.
- No IAmina runtime/Core modification: **met**.

### PROOF

Primary LOT 02 artifact:

`docs/ocd/lots/LOT_02_CLIENT_ISOLATION_CAPSULE_CONTRACT.md`

Specialist review:

`docs/ocd/reviews/LOT_02_SPECIALIST_REVIEW.md`

Draft PR:

`#3 — docs: LOT 02 define TrueGround client isolation and OCD capsule contract`

Current IAmina source inspected for this lot:

- Repository: `hraaaaf/IAMINA-MVP`
- Branch: `main`
- Inspected HEAD: `4e7b04a3387da68374e00ab858e63b914faa1884`

LOT 01 IAmina inspection baseline was:

`715e2cc5108992f1347e93a115b0c71c90f47914`

The current IAmina HEAD was verified as 4 commits ahead / 0 behind that prior baseline, and the changed files in that range did not include the Core/backend architecture surfaces re-inspected for LOT 02.

## 3. What was done

LOT 02:

- re-read the LOT 01 handover, inspection and specialist review;
- re-read the canonical architecture/privacy/roadmap/gates/review/handover documents;
- verified live TrueGround default branch, canonical branch, LOT 01 branch, PRs, divergence, CI/status and review-thread state;
- re-checked current IAmina `main` and compared it to the LOT 01 inspected revision;
- re-inspected concrete IAmina backend/frontend composition and Core seams;
- recorded Option A as the concrete architecture contract rather than introducing Option B;
- distinguished reusable generic primitives from the existing Diabetes application composition;
- defined separate TrueGround runtime/data/auth/memory/provider/config/frontend boundaries;
- defined Core vs OCD ownership and forbidden dependency directions;
- defined a non-floating immutable-source-revision update strategy without pretending an independently published Core package already exists;
- defined the future executable checks required to prevent OCD leakage into Core, Diabetes packaging/coupling in TrueGround, and cross-client state/config access;
- ran explicit separate adversarial Architecture, Data/Privacy/Security, OCD Safety and QA/Non-regression review passes;
- opened a dedicated draft PR for LOT 02.

## 4. What was NOT done

LOT 02 did **not**:

- modify `hraaaaf/IAMINA-MVP`;
- change IAmina Core;
- extract or publish a shared Core package;
- create a TrueGround backend or frontend runtime;
- choose a concrete Core packaging mechanism;
- create exact OCD API routes;
- create database tables, schema or migrations;
- create memory persistence schema;
- design or implement the Loop UI;
- design or implement Compulsion Firewall behavior;
- design or implement ERP/practice behavior;
- define a crisis protocol;
- choose an LLM/model/provider for TrueGround;
- create production infrastructure;
- mutate any database, secrets or real user data;
- deploy to Vercel, TestFlight, Play Store or any external environment;
- merge PR #1, #2 or #3;
- start LOT 03;
- create `docs/ocd/handovers/LOT_03_START_PROMPT.md` because LOT 03 execution has not been explicitly authorized in this window.

## 5. Files changed

LOT 02 branch adds:

- `docs/ocd/lots/LOT_02_CLIENT_ISOLATION_CAPSULE_CONTRACT.md`
- `docs/ocd/reviews/LOT_02_SPECIALIST_REVIEW.md`
- `docs/ocd/handovers/LOT_02_HANDOVER.md`

No runtime source, dependency manifest, schema, CI workflow or production configuration is changed by LOT 02.

## 6. Tests and non-regression

### Repository-state checks executed

TrueGround:

- verified default branch `main` and exact HEAD;
- verified canonical foundation branch and exact HEAD;
- verified LOT 01 branch and exact HEAD;
- compared canonical foundation against `main`;
- compared LOT 01 against canonical foundation;
- inspected PR #1 and PR #2 exact open/draft/not-merged state;
- checked unresolved review threads/comments for existing PRs;
- checked combined commit statuses for relevant TrueGround heads;
- created LOT 02 from exact LOT 01 HEAD;
- compared LOT 02 branch against LOT 01 before handover;
- checked PR #3 state, review threads/comments, status contexts and workflow runs before handover.

IAmina:

- verified `hraaaaf/IAMINA-MVP main` exact current HEAD;
- compared prior LOT 01 inspected SHA to current `main`;
- re-inspected current source for Core/module registry, import boundary, companion ports, AI egress, LLM gateway/provider factory, patient/account/module state, deletion hooks, Diabetes startup composition, backend settings and Flutter module composition.

### Branch diff before handover commit

- base: `lot/01-iamina-core-inspection` at `c5380cae770c11b958cb4a0a54152da40030df71`
- head: `lot/02-client-isolation-capsule-contract` at `47c40b7e23d3d4aca4219a83610c47bc23b7a66f`
- ahead: `2`
- behind: `0`
- changed files: `2`
- additions: `836`
- deletions: `0`
- changed paths were documentation only:
  - `docs/ocd/lots/LOT_02_CLIENT_ISOLATION_CAPSULE_CONTRACT.md`
  - `docs/ocd/reviews/LOT_02_SPECIALIST_REVIEW.md`

### CI/check state before handover commit

For LOT 02 HEAD `47c40b7e23d3d4aca4219a83610c47bc23b7a66f`:

- combined status contexts observed: none;
- PR-triggered workflow runs observed: none;
- PR #3 unresolved review threads observed: none;
- PR #3 conversation/review comments observed: none.

This must not be described as “green CI”; no CI/status checks were attached to the inspected HEAD.

### Non-regression statement

LOT 02 modifies only TrueGround documentation.

No TrueGround runtime exists in the repository today, and no IAmina runtime/Core code was modified. Therefore no application behavior, database, schema, dependency, provider setting, secret or production configuration was changed by this lot.

No full IAmina test suite was rerun because IAmina source was read-only in LOT 02. This is a deliberate limitation, not a passing runtime-test claim.

Future implementation of the contract must execute the isolation/import/composition/access/deletion checks defined in the LOT 02 artifact before the relevant gates can become verified.

## 7. Specialist review ledger

Canonical LOT 02 review artifact:

`docs/ocd/reviews/LOT_02_SPECIALIST_REVIEW.md`

| Reviewer | Verdict | Evidence | Unresolved note |
|---|---|---|---|
| ARCHITECTURE_AGENT | PASS_WITH_NOTES | current IAmina source + LOT 02 contract | no independently packaged Core exists; concrete client composition/packaging remains an implementation decision; re-check IAmina freshness before implementation |
| DATA_PRIVACY_SECURITY_AGENT | PASS_WITH_NOTES | isolation contract + current auth/data/memory/provider evidence | future infrastructure must prove distinct project/database/storage/auth/config boundaries without exposing secrets |
| OCD_SAFETY_AGENT | PASS_WITH_NOTES | Core/OCD ownership + prompt/eval/AI boundary | generic “loop/rate” infrastructure must never absorb OCD loop/reassurance/checking/rumination semantics |
| QA_NON_REGRESSION_AGENT | PASS | docs-only branch diff + IAmina read-only inspection | no runtime tests exist for TrueGround yet; no IAmina suite rerun because IAmina was unchanged |

### Review-method limitation

No independent sub-agent execution interface was available in this window.

The mandatory roles were therefore executed as separate explicit adversarial review passes rather than falsely claiming an independent human/model reviewer. The artifact remains `READY FOR REVIEW`; the appropriate external/product-owner gate still has the final verification role.

## 8. Current risks / blockers

### R1 — Shared Core is not yet an independently packaged artifact

The inspected repository has reusable Core seams but the current application composition directly includes Diabetes. LOT 02 deliberately does not invent a package-extraction solution.

### R2 — Client composition remains to be implemented and proven

Current backend settings include `diabetes.apps.DiabetesConfig` and Diabetes middleware; the Flutter module registry statically imports Diabetes. Future TrueGround runtime work must construct and test a separate composition rather than reuse those files unchanged.

### R3 — AI egress purpose registration is currently hard-coded

OCD-specific purpose constants must not be inserted into shared Core. If existing genuinely generic purposes are insufficient, a separately reviewed generic registration/configuration seam may be required.

### R4 — Contract checks are not yet executable against TrueGround runtime

TrueGround currently has no application runtime in the repository. The future import/composition/access/deletion/isolation tests are defined but cannot honestly be reported as passing today.

### R5 — IAmina source may move before implementation

The LOT 02 inspected SHA is an evidence baseline, not permission to skip the next-window freshness check. Any future implementation must inspect the then-current IAmina source and relevant diff before choosing or advancing an immutable Core source revision.

### R6 — Clinical/OCD behavior remains deliberately unresolved

No reassurance, checking, rumination, Compulsion Firewall, ERP or crisis behavior was defined here. Those require later OCD-safety/eval and, where applicable, qualified clinical/regulatory review.

## 9. Repository truth at handover preparation

### TrueGround main

- default branch: `main`
- HEAD: `e1cdd5485e80c3c8bb4f7f5e3bdf695709111d61`

### Canonical foundation

- branch: `docs/ocd-canonical-foundation`
- HEAD: `5921c4b5b89426a41d8100919511593cdcbc40b9`
- versus `main`: ahead 20 / behind 0
- PR #1: OPEN / DRAFT / NOT MERGED

### LOT 01

- branch: `lot/01-iamina-core-inspection`
- HEAD: `c5380cae770c11b958cb4a0a54152da40030df71`
- versus canonical foundation: ahead 5 / behind 0
- PR #2: OPEN / DRAFT / NOT MERGED

### LOT 02 before handover commit

- branch: `lot/02-client-isolation-capsule-contract`
- HEAD: `47c40b7e23d3d4aca4219a83610c47bc23b7a66f`
- versus LOT 01: ahead 2 / behind 0
- PR #3: OPEN / DRAFT / NOT MERGED
- PR #3 base: `lot/01-iamina-core-inspection`
- PR #3 changed files: 2
- PR #3 additions/deletions: 836 / 0
- combined status contexts: none observed
- PR-triggered workflow runs: none observed
- unresolved review threads: none observed
- PR comments/reviews in merged discussion feed: none observed

### IAmina source inspected

- repository: `hraaaaf/IAMINA-MVP`
- branch: `main`
- inspected HEAD: `4e7b04a3387da68374e00ab858e63b914faa1884`
- versus LOT 01 inspected SHA `715e2cc5108992f1347e93a115b0c71c90f47914`: ahead 4 / behind 0

These are snapshots. The handover commit itself advances LOT 02 HEAD, and all values must be re-checked before any future action.

## 10. Next lot

LOT 02 stops here.

The canonical roadmap places an application-shell/design-foundation phase after the architecture contract, but **LOT 03 execution has not been explicitly authorized in this window**.

Therefore:

- no LOT 03 implementation is started;
- no `LOT_03_START_PROMPT.md` is created;
- the product owner should first review LOT 02 / PR #3 and explicitly define/authorize the next lot scope.

No handover state or specialist verdict authorizes merge or deployment.

# Closeout

## Résultat

Approved Option A has been converted into a concrete, auditable architecture contract: TrueGround may reuse inspected generic IAmina Core primitives while remaining a physically/logically separate client runtime/data plane from Diabetes. Current Diabetes-coupled backend/frontend composition is explicitly excluded from unchanged reuse.

## Modifications

Three TrueGround documentation artifacts only: LOT 02 contract, specialist review ledger, and this handover. IAmina source unchanged.

## Tests

Live repository/PR/divergence/status/thread checks, current IAmina source re-inspection, old→current IAmina diff inspection, LOT 02 branch diff inspection, and four explicit adversarial specialist review passes.

No runtime test suite was executed because LOT 02 contains no runtime source change and TrueGround has no runtime implementation yet.

## Non-régression

No application runtime, schema, database, dependency, secret, provider or production configuration was changed. Diabetes behavior was not modified.

## Preuves

- LOT 02 contract artifact;
- LOT 02 specialist review artifact;
- draft PR #3;
- pre-handover HEAD `47c40b7e23d3d4aca4219a83610c47bc23b7a66f`;
- IAmina inspected HEAD `4e7b04a3387da68374e00ab858e63b914faa1884`;
- documentation-only branch diff;
- explicit absence of attached CI/status checks recorded rather than misreported as green.

## Risques

Concrete Core packaging/client composition, runtime isolation tests, future egress-purpose extensibility and all OCD behavioral/clinical implementation remain future reviewed work.

## État

`READY FOR REVIEW`

## Prochaine étape

Product-owner review of LOT 02 / PR #3. Do not merge. If accepted, explicitly define and authorize LOT 03 in a fresh window; re-check all repository and IAmina state before modifying anything.
